nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

04.07.2022 | comment

Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

verfasst von: Isabel Heidegger, MD, PhD, Andreas Pircher

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editors, …

Vorheriger Artikel Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

Nächster Artikel Focal therapy in intermediate- and high-risk prostate cancer

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–42; https://doi.org/10.1056/NEJMoa2119115.CrossRefPubMedPubMedCentral

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040–9.CrossRefPubMed

Abbasi A, Movahedpour A, Amiri A, Najaf MS, Mostafavi-Pour Z. Darolutamide as a second-generation androgen receptor inhibitor in the treatment of prostate cancer. Curr Mol Med. 2021;21(4):332–46.PubMed

Fizazi K, Maldonado X, Foulon S, Roubaud G, McDermott RS, Flechon A, et al. A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE‑1. J Clin Oncol. 2021;39(15_suppl):5000.CrossRef

Titel: Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
verfasst von: Isabel Heidegger, MD, PhD
Andreas Pircher
Publikationsdatum: 04.07.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00820-x

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

ASCO 2023—partnering with patients: the cornerstone of cancer care and research

Editorial

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction